期刊文献+

吡格列酮对高脂饮食兔主动脉LOX-1表达的影响 被引量:6

Effects of Pioglitazone on expression of LOX-1 in aorta of high-cholesterol diet rabbits
下载PDF
导出
摘要 目的探讨吡格列酮对高脂饮食下兔主动脉LOX-1表达的影响及其对动脉粥样硬化的作用。方法设立正常饮食、高脂饮食及高脂饮食加吡格列酮干预3组,通过比较主动脉病理形态学改变、血脂的变化、LOX-1分子及mRNA的表达进行研究,采用免疫组化检测兔主动脉LOX-1分子的表达,采用RT-PCR检测LOX-1mRNA的表达。结果吡格列酮能减轻高脂饮食所致的内膜增厚和平滑肌增生,减轻高脂血症所致动脉粥样硬化的发展。吡格列酮还能明显升高HDL,对TC、LDL、TG和BS无明显影响。高脂饮食刺激兔主动脉LOX-1分子及mRNA的表达,吡格列酮能显著减轻这种作用。结论吡格列酮能减轻高脂饮食兔主动脉LOX-1分子及mRNA的表达,这可能是噻唑烷酮类药物抗动脉粥样硬化的重要作用机制。 [Objective] To explore the effects of Pioglitazone on atherosclerosis and the expression LOX-1 in aorta of rabbits fed with high-cholesterol diet. [Method] 15 male healthy New Zealand rabbits were randomly divided into three groups: control group(n =5)was fed with normal diet for eight weeks; high cholesterol group(n =5) was fed with high-cholesterol diet for eight weeks; Pioglitazone treatment group(n =5) was fed with high-cholesterol diet for eight weeks supplemented with Pioglitazone(3 mg/kg·d) from the fourth week of cholesterol diet. The aortic pathological menifestation and plasma lipid in these groups were compared. LOX-1 molecule was detected by immunohistochemistry, LOX-1 mRNA was evaluated by reverse transcription-polymerase chain reaction(RT-PCR). [Results] Pioglitazone decreased aortic intimal hyperplasia and smooth muscle cell proliferation in rabbit fed with high-cholesterol diet. Pioglitazone can also increase high density lipoprotein and decrese the expression of LOX-1 molecule and LOX-1 mRNA in the aorta of hypercholesterolemia rabbits aortic. [Conclusion] Pioglitazone can inhibit the upregulation of LOX-1 molecule and mRNA in the aorta of hypercholesterolemia rabbits. These observations provide novel insight into a potential antiatherosclerosis pathway of Thiazolidinediones.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2008年第10期1342-1345,1349,共5页 China Journal of Modern Medicine
关键词 吡格列酮 高脂饮食 动脉粥样硬化 血凝素样氧化低密度脂蛋白受体(LOX-1) Pioglitazone high-cholesterol diet atherosclerosis LOX-1
  • 相关文献

参考文献2

二级参考文献18

  • 1陆金春,冯大新,尹兴昌.肺炎衣原体感染与动脉粥样硬化相关性的研究进展(英文)[J].中国现代医学杂志,2004,14(18):48-54. 被引量:7
  • 2Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation, 1998,97: 916-931.
  • 3Mehta JL, Li D. Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor. J Am Coll Cardiol, 2002, 39: 1429-1435.
  • 4Kataoka H, Kume N, Miyamoto S, et al. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation,1999, 99: 3110-3117.
  • 5Li DY, Zhang YC, Philips MI, et al. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. Circ Res, 1999, 84: 1043-1049.
  • 6Chen H, Li D, Sawamura T, et al. Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan. Biochem Biophys Res Commun, 2000,276: 1100-1104.
  • 7Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation, 2000, 101: 1586-1593.
  • 8Hayek T, Attias J, Coleman R, et al. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotei
  • 9Keidar S, Attias J, Smith J, et al. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun, 1997,236: 622-625.
  • 10VANHOUTTE PM.Endothelial dysfunction and atherosclerosis[J].Arch Mal Coeur Vaiss,1997,90(6):9-19.

共引文献19

同被引文献63

  • 1刘尊敬,杨期东,刘运海,王国相,焦劲松,薛爽,田朝晖,熊新英,龙涛,徐文艳.过氧化小体增殖剂激活型受体γ激活剂对缺血再灌注脑组织的保护作用及炎性机制分析[J].国际神经病学神经外科学杂志,2007,34(2):121-124. 被引量:16
  • 2刘尊敬,杨期东,刘运海,王国相,焦劲松,田朝晖,龙涛,徐文艳.PPARγ激活剂对大鼠缺血再灌注脑组织的保护作用及对PPARγ表达的影响[J].中风与神经疾病杂志,2007,24(2):132-135. 被引量:16
  • 3张茜,范廷璐,刘可琢,何芳芳,苏一星,邢大平,李波,陈素仙,贾俊海.糖尿病与吡格列酮对心肌缺血再灌注损伤的影响及其机制[J].江苏大学学报(医学版),2007,17(3):232-235. 被引量:2
  • 4Florian Blaschke MD, Evren Caglayan MD, Willa A, et al. Peroxisomeproliferator-Activated Receptor Gamma Agonists:Their Role as Vasoprotective Agents in Diabetes. Endocrinol Metab Clin North Am ,2006,35 ( 3 ) :561-574.
  • 5Sato Y, Asada Y, Marutsuka K, et al. Tissue factor induces migration of cultured aortic smooth muscle cells[J]. Thromb Haemost, 1996, 75(3):389-392.
  • 6Cirillo P, Cali G, Golino P, et al. Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation[J]. Circulation, 2004, 109(23):2911-2916.
  • 7Felmeden DC, Spencer CG, Chung NA, et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT])[J]. Am J Cardiol, 2003, 92(4): 400-405.
  • 8Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention[J]. Circulation, 2004, 109(21):2524-2528.
  • 9Sambola A, Osende J, Hathcock J, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity[J]. Circulation, 2003, 107(7):973-977.
  • 10Lutgens E, van Suylen RJ, Faber BC, et al. Atherosclerotic plaque rupture: local or systemic process?[J]. Arterioscler Thromb Vasc Biol, 2003, 23(12):2123-2130.

引证文献6

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部